Patents by Inventor Margaret D. Moore
Margaret D. Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200023057Abstract: Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.Type: ApplicationFiled: July 16, 2019Publication date: January 23, 2020Inventors: Thomas W. Dubensky, JR., Nancy A. Hosken, Scott H. Robbins, Margaret D. Moore
-
Patent number: 10391164Abstract: Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.Type: GrantFiled: December 14, 2016Date of Patent: August 27, 2019Assignee: IMMUNE DESIGN CORP.Inventors: Thomas W. Dubensky, Jr., Nancy A. Hosken, Scott H. Robbins, Margaret D. Moore
-
Patent number: 9895435Abstract: Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.Type: GrantFiled: May 16, 2013Date of Patent: February 20, 2018Assignee: IMMUNE DESIGN CORP.Inventors: Thomas W. Dubensky, Jr., Nancy A. Hosken, Scott H. Robbins, Margaret D. Moore
-
Publication number: 20170274066Abstract: Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.Type: ApplicationFiled: December 14, 2016Publication date: September 28, 2017Applicant: IMMUNE DESIGN CORP.Inventors: Thomas W. Dubensky, JR., Nancy A. Hosken, Scott H. Robbins, Margaret D. Moore
-
Patent number: 9555099Abstract: Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.Type: GrantFiled: May 16, 2013Date of Patent: January 31, 2017Assignee: IMMUNE DESIGN CORP.Inventors: Thomas W. Dubensky, Jr., Nancy A. Hosken, Scott H. Robbins, Margaret D. Moore
-
Patent number: 8907068Abstract: The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.Type: GrantFiled: May 21, 2008Date of Patent: December 9, 2014Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Zhi Chen, Steven D. Hughes, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavar V. Sivakumar, Margaret D. Moore
-
Patent number: 8822642Abstract: Compositions and methods relating to soluble dimeric proteins are disclosed. The dimeric proteins comprise first and second polypeptide fusions linked via a dimerizing domain, each polypeptide fusion comprising first and second monomer domains corresponding to a cytokine or an extracellular domain of a cell-surface receptor. The monomer domains may be positioned amino terminal and carboxyl terminal to the dimerizing domain. Alternatively, the monomer domains may be positioned in tandem, either carboxyl terminal or amino terminal to the dimerizing domain. The dimeric proteins are useful in methods for therapy, diagnosis, and research.Type: GrantFiled: June 7, 2011Date of Patent: September 2, 2014Assignee: ZymoGenetics, Inc.Inventors: Steven D. Levin, Margaret D. Moore, Craig D. Ostrander, Katherine E. Lewis, David W. Taft, Robert J. Rosler, Anitra Wolf, Megan M. Lantry
-
Publication number: 20140127247Abstract: Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.Type: ApplicationFiled: May 16, 2013Publication date: May 8, 2014Applicant: IMMUNE DESIGN CORP.Inventors: Thomas W. Dubensky, JR., Nancy A. Hosken, Scott H. Robbins, Margaret D. Moore
-
Patent number: 8536309Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: GrantFiled: January 12, 2012Date of Patent: September 17, 2013Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret D. Moore
-
Publication number: 20130095102Abstract: Compositions and methods relating to soluble dimeric proteins are disclosed. The dimeric proteins comprise first and second polypeptide fusions linked via a dimerizing domain, each polypeptide fusion comprising first and second monomer domains corresponding to a cytokine or an extracellular domain of a cell-surface receptor. The monomer domains may be positioned amino terminal and carboxyl terminal to the dimerizing domain. Alternatively, the monomer domains may be positioned in tandem, either carboxyl terminal or amino terminal to the dimerizing domain. The dimeric proteins are useful in methods for therapy, diagnosis, and research.Type: ApplicationFiled: June 7, 2011Publication date: April 18, 2013Applicant: ZymoGenetics, Inc.Inventors: Steven D. Levin, Margaret D. Moore, Craig D. Ostrander, Katherine E. Lewis, David W. Taft, Robert J. Rosler, Anitra Wolf, Megan M. Lantry
-
Patent number: 8163286Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: GrantFiled: October 16, 2009Date of Patent: April 24, 2012Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret D. Moore
-
Publication number: 20110263484Abstract: The present invention relates to single chain Fc Type III Interferon fusion proteins and methods of using same. The single chain Fc Type III Interferon fusion proteins comprise at least one Type III Interferon, two Fc regions and at least one linker, can be produced in a variety of single chain configurations, and are effector function minus or have a substantially reduced effector function.Type: ApplicationFiled: October 13, 2009Publication date: October 27, 2011Inventors: Margaret D. Moore, Michael G. Dodds, Paul O. Sheppard, Henrik Andersen
-
Publication number: 20110081345Abstract: The present invention relates generally to scFc molecules. The scFc molecules comprise at least two Fc regions and at least one linker, and can be produced in a variety of single chain configurations. The scFc molecules can further comprise at least one binding entity and/or at least one functional molecule. Binding entities can be fused to the scFc molecule in a variety of configurations. The present invention also relates generally to methods for making such molecules and methods for their use. The scFc molecules provided herein can be recombinantly produced. Also provided are monovalent forms of the scFc molecules that have an equivalent or superior ADCC and/or CDC response than do bivalent molecules targeting the same antigens. Provided herein are improved antigen binding compositions.Type: ApplicationFiled: November 8, 2010Publication date: April 7, 2011Inventors: Margaret D. Moore, Marshall D. Snavely, Brian A. Fox
-
Patent number: 7763445Abstract: Polypeptide fusions, dimeric fusion proteins, and materials and methods for making them are disclosed. One of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, a dimerizing domain, and, optionally, a linking polypeptide. Another of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, and a second dimerizing domain.Type: GrantFiled: April 21, 2008Date of Patent: July 27, 2010Assignee: ZymoGenetics, Inc.Inventors: Margaret D. Moore, Brian A. Fox
-
Publication number: 20100111948Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: ApplicationFiled: October 16, 2009Publication date: May 6, 2010Applicant: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret D. Moore
-
Publication number: 20100093076Abstract: Polypeptides and proteins comprising an IL-27RA cytokine binding domain operably linked to an immunoglobulin Fc fragment are disclosed. The Fc fragment is a modified Fc fragment wherein amino acid residues at EU index postions 234, 235, and 237 have been substituted to reduce binding to Fc?RI and amino acid residues at EU index positions 330 and 331 have been substituted to reduce complement fixation. The proteins can be used medicinally for modulating immune responses, such as within methods of treating autoimmune diseases.Type: ApplicationFiled: August 27, 2007Publication date: April 15, 2010Inventor: Margaret D. Moore
-
Publication number: 20100008917Abstract: Methods of treating aplastic anemia in a patient and of increasing blood cell production in a patient having aplastic anemia are disclosed. The methods comprise administering to the patient a therapeutically effective amount of an IL-27 antagonist in combination with a pharmaceutically acceptable vehicle. IL-27 antagonists include soluble IL-27RA proteins and antagonists that comprise an antigen-binding site of an antibody.Type: ApplicationFiled: August 27, 2007Publication date: January 14, 2010Inventors: Nancy Hosken, Kelly Byrnes-Blake, Ty Brender, Monica J. Huber, Margaret D. Moore, Shirley Rene, Mark W. Rixon, Sara Underwood
-
Publication number: 20090074661Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: ApplicationFiled: July 21, 2008Publication date: March 19, 2009Inventors: Wenfeng Xu, Wayne Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret D. Moore
-
Publication number: 20090075338Abstract: Polypeptide fusions, dimeric fusion proteins, and materials and methods for making them are disclosed. One of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, a dimerizing domain, and, optionally, a linking polypeptide. Another of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, and a second dimerizing domain.Type: ApplicationFiled: April 21, 2008Publication date: March 19, 2009Inventors: Margaret D. Moore, Brian A. Fox
-
Publication number: 20080260738Abstract: The present invention relates generally to scFc molecules. The scFc molecules comprise at least two Fc regions and at least one linker, and can be produced in a variety of single chain configurations. The scFc molecules can further comprise at least one binding entity and/or at least one functional molecule. Binding entities can be fused to the scFc molecule in a variety of configurations. The present invention also relates generally to methods for making such molecules and methods for their use. The scFc molecules provided herein can be recombinantly produced. Also provided are monovalent forms of the scFc molecules that have an equivalent or superior ADCC and/or CDC response than do bivalent molecules targeting the same antigens. Provided herein are improved antigen binding compositions.Type: ApplicationFiled: April 18, 2008Publication date: October 23, 2008Inventors: Margaret D. Moore, Marshall D. Snavely, Brian A. Fox, Gabriela H. Hoyos